356 related articles for article (PubMed ID: 34012442)
1. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
Front Immunol; 2021; 12():658314. PubMed ID: 34012442
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic Analysis of CAR-T Cells.
de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
6. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
Mihara K; Yoshida T; Bhattacharyya J
Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
[TBL] [Abstract][Full Text] [Related]
7. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
9. Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect staining.
Zaninelli S; Meli C; Borleri G; Quaroni M; Pavoni C; Gaipa G; Biondi A; Introna M; Golay J; Rambaldi A; Rambaldi B
Cytometry A; 2024 Feb; 105(2):112-123. PubMed ID: 37707318
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
13. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
14. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
Xu C; Yin Y
Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P
Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918
[No Abstract] [Full Text] [Related]
17. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
18. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
[TBL] [Abstract][Full Text] [Related]
19. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
20. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
